Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
Aptinyx Inc. (Nasdaq: APTX) has announced a conference call scheduled for August 10, 2021, at 5:00 p.m. ET to discuss its second-quarter 2021 financial results and recent business highlights.
The call will be accessible via phone or a live audio webcast on the company's website. Aptinyx specializes in developing therapies for nervous system disorders, with three products in clinical development targeting chronic pain, PTSD, and cognitive impairment.
- Aptinyx has three product candidates in clinical development addressing significant medical needs in central nervous system disorders.
- The company utilizes a unique mechanism to modulate NMDA receptors, potentially enhancing efficacy.
- None.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report second quarter 2021 financial results and discuss recent business highlights.
To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 2576236. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.
Source: Aptinyx Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005079/en/
FAQ
When will Aptinyx report its second quarter 2021 financial results?
How can I access the Aptinyx conference call?
What is Aptinyx's focus in the biopharmaceutical field?
